Margetuximab with retifanlimab as first-line therapy in HER2+/PD-L1+ unresectable or metastatic gastroesophageal adenocarcinoma: MAHOGANY cohort A

[1]  L. Shen,et al.  Safety and efficacy of HER2 blockade by trastuzumab-based chemotherapy-containing combination strategies in HER2+ gastroesophageal adenocarcinoma , 2021, ESMO open.

[2]  E. Van Cutsem,et al.  The KEYNOTE-811 trial of dual PD-1 and HER2 blockade in HER2-positive gastric cancer , 2021, Nature.

[3]  Sung-Bae Kim,et al.  Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study , 2021, The Lancet.

[4]  J. Ajani,et al.  First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial , 2021, The Lancet.

[5]  F. Lordick,et al.  Biomarker-targeted therapies for advanced-stage gastric and gastro-oesophageal junction cancers: an emerging paradigm , 2021, Nature Reviews Clinical Oncology.

[6]  J. Hasenauer,et al.  HER2 Expression, Test Deviations, and Their Impact on Survival in Metastatic Gastric Cancer: Results From the Prospective Multicenter VARIANZ Study , 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  Yoon-Koo Kang,et al.  MAHOGANY: margetuximab combination in HER2+ unresectable/metastatic gastric/gastroesophageal junction adenocarcinoma. , 2020, Future oncology.

[8]  Y. Bang,et al.  Efficacy and Safety of Pembrolizumab or Pembrolizumab Plus Chemotherapy vs Chemotherapy Alone for Patients With First-line, Advanced Gastric Cancer: The KEYNOTE-062 Phase 3 Randomized Clinical Trial. , 2020, JAMA oncology.

[9]  J. Lacy,et al.  Margetuximab plus pembrolizumab in patients with previously treated, HER2-positive gastro-oesophageal adenocarcinoma (CP-MGAH22-05): a single-arm, phase 1b-2 trial. , 2020, The Lancet. Oncology.

[10]  Hyo Song Kim,et al.  Targeting HER2 in combination with anti-PD-1 and chemotherapy confers a significant tumor shrinkage of gastric cancer: A multi-institutional phase Ib/II trial of first-line triplet regimen (pembrolizumab, trastuzumab, chemotherapy) for HER2-positive advanced gastric cancer (AGC). , 2020 .

[11]  B. Taylor,et al.  First-line pembrolizumab and trastuzumab in HER2-positive oesophageal, gastric, or gastro-oesophageal junction cancer: an open-label, single-arm, phase 2 trial. , 2020, The Lancet. Oncology.

[12]  Sang-Hoon Ahn,et al.  PD-L1 Testing in Gastric Cancer by the Combined Positive Score of the 22C3 PharmDx and SP263 Assay with Clinically Relevant Cut-offs , 2020, Cancer research and treatment : official journal of Korean Cancer Association.

[13]  R. Emerson,et al.  High frequency of HER2-specific immunity observed in patients (pts) with HER2+ cancers treated with margetuximab (M), an Fc-enhanced anti-HER2 monoclonal antibody (mAb). , 2019, Journal of Clinical Oncology.

[14]  M. Shah,et al.  Pertuzumab plus trastuzumab and chemotherapy for HER2-positive metastatic gastric or gastro-oesophageal junction cancer (JACOB): final analysis of a double-blind, randomised, placebo-controlled phase 3 study. , 2018, The Lancet. Oncology.

[15]  G. Calin,et al.  Trastuzumab upregulates PD-L1 as a potential mechanism of trastuzumab resistance through engagement of immune effector cells and stimulation of IFNγ secretion. , 2018, Cancer letters.

[16]  J. Lunceford,et al.  Clinical Utility of the Combined Positive Score for Programmed Death Ligand-1 Expression and the Approval of Pembrolizumab for Treatment of Gastric Cancer. , 2018, Archives of pathology & laboratory medicine.

[17]  Kazuhiro Yoshida,et al.  Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial , 2018, The Lancet.

[18]  P. Philip,et al.  Safety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer: Phase 2 Clinical KEYNOTE-059 Trial , 2018, JAMA oncology.

[19]  M. Shah,et al.  HELOISE: Phase IIIb Randomized Multicenter Study Comparing Standard-of-Care and Higher-Dose Trastuzumab Regimens Combined With Chemotherapy as First-Line Therapy in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  S. Kakar,et al.  HER2 Testing and Clinical Decision Making in Gastroesophageal Adenocarcinoma: Guideline From the College of American Pathologists, American Society for Clinical Pathology, and the American Society of Clinical Oncology. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  Y. Bang,et al.  Mass-spectrometry-based quantitation of Her2 in gastroesophageal tumor tissue: comparison to IHC and FISH , 2016, Gastric Cancer.

[22]  A. Blackler,et al.  Quantitative proteomic analysis of HER2 expression in the selection of gastric cancer patients for trastuzumab treatment , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

[23]  M. Hidalgo,et al.  Level of HER2 gene amplification predicts response and overall survival in HER2-positive advanced gastric cancer treated with trastuzumab. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  P. Moore,et al.  Anti-tumor activity and toxicokinetics analysis of MGAH22, an anti-HER2 monoclonal antibody with enhanced Fcγ receptor binding properties , 2011, Breast Cancer Research.

[25]  Yoon-Koo Kang,et al.  Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial , 2010, The Lancet.

[26]  J. Stavenhagen,et al.  Fc optimization of therapeutic antibodies enhances their ability to kill tumor cells in vitro and controls tumor expansion in vivo via low-affinity activating Fcgamma receptors. , 2007, Cancer research.